Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (602)	6/29/1999 5:56:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

Aids Dementia Complex in the AIDS Cocktail era. There has been considerable debate as to whether the new antiretroviral therapies for AIDS would suppress the virus to such an extent that the dementia symptoms would be eliminated or would never develop, or whether the virus in the brain would be protected from the drugs by the blood brain barrier and thus ADC would become a major problem. The answer to this question will determine the need for NTII's memantine for the treatment of ADC. There is an excellent article discussing this issue in this months Medscape HIV update issue: Neurological Disorders - Justin McArthur, MBBS, MPH - [Medscape HIV/AIDS 5(Supplement):1999 Annual Update. medscape.com Here is a quote from the article that is pertinent to the use of memantine for ADC. "Adjunctive and Symptomatic Treatments A large group of "adjunctive" agents has been developed based on advances in our understanding of the pathophysiologic mechanisms of HIV dementia. It seems likely that in the future, effective and sustained treatment of established dementia will require both antiretroviral and agents targeting neuron-damaging pathophysiologic mechanisms. Several experimental treatments have been tried or are currently being studied (see Table II). The data at this stage, however, are too preliminary to make definite management suggestions. Larger studies will be needed to develop this information. Adjunctive therapies which may block the pathophysiologic changes in the brain include the NMDA receptor antagonist memantine (in trial now in ACTG 301), and seligiline, an anti-Parkinsonian agent with putative anti-apoptotic properties." John de C